A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors
Status:
NOT_YET_RECRUITING
Trial end date:
2029-04-21
Target enrollment:
Participant gender:
Summary
This is a single-center, single-arm ，open-label ，dose escalation and dose extension study. In this study we plan to evaluate the safety and efficacy of CD70-targeting UCAR-T cells in the treatment of CD70-positive refractory or relapsed solid tumors, and obtain recommended doses and infusion patterns.